This week on Pharm5:

  • Farxiga (dapagliflozin) for HFpEF
  • Updated boosters for COVID-19
  • Xenpozyme (olipudase alfa) for rare ASMD
  • New York Times on “growing chains, falling wages”
  • Phase III olokizumab vs. adalimumab for RA

Connect with us!

  • Listen to our podcast: Pharm5
  • Watch us on TikTok: @LizHearnPharmD
  • Follow us on Twitter: @LizHearnPharmD

References

  1. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. August 2022. doi:10.1056/nejmoa2206286
  2. FDA Approves Treatment for Wider Range of Patients with Heart Failure https://bit.ly/3B20I8N. Published February 24, 2022. Accessed February 24, 2022.
  3. Coronavirus (COVID-19) update: FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose. U.S. Food and Drug Administration. https://bit.ly/3cDuyHd. Accessed August 31, 2022.
  4. Scheiber N. How pharmacy work stopped being so great. The New York Times. https://www.nytimes.com/2022/08/20/business/economy/pharmacists-job-inflation.html. Published August 20, 2022. Accessed September 1, 2022.
  5. FDA approves first treatment for acid sphingomyelinase deficiency, a rare genetic disease. U.S. Food and Drug Administration. https://bit.ly/3AziPS5. Accessed August 31, 2022.
  6. Dunleavy K. Sanofi's rare disease drug XENPOZYME scores FDA approval after nods in Japan and Europe. Fierce Pharma. https://bit.ly/3B3kz7F. Published August 31, 2022. Accessed August 31, 2022.
  7. Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine. 2022;387(8):715-726. doi:10.1056/nejmoa2201302

See All 59 Episodes of "Pharm5"